Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: A systematic review

Transfusion

Volumn 53, Issue 10, 2013, Pages 2230-2242

  Pavenski, Katerina ^a   Rebulla, Paolo ^b   Duquesnoy, Rene ^b   Saw, Chee Loong ^b   Slichter, Sherrill J ^b   Tanael, Susano ^b   Shehata, Nadine ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY;

ACCURACY; ALLOIMMUNIZATION; BLEEDING; DISEASE SEVERITY; HLA MATCHING; HUMAN; HYPOPROLIFERATIVE THROMBOCYTOPENIA; LABORATORY TEST; MORTALITY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; RETROSPECTIVE STUDY; REVIEW; SAMPLE SIZE; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

HISTOCOMPATIBILITY TESTING; HUMANS; PLATELET TRANSFUSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOCYTOPENIA;

EID: 84885860277     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12175     Document Type: Review

References (51)

1. Aster RH, Levin RH, Cooper H, Freireich EJ,. Complement-fixing platelet iso-antibodies in serum of transfused persons. Correlation of antibodies with platelet survival in thrombocytopenic patients. Transfusion 1964; 4: 428-440.
2. Shulman NR,. Immunological considerations attending platelet transfusion. Transfusion 1966; 6: 39-49.
3. Yankee RA, Grumet FC, Rogentine GN,. The selection of compatible platelet donors for refractory patients by lymphocyte HLA typing. N Engl J Med 1969; 281: 1208-1212.
4. Yankee RA, Graff KS, Dowling R, Henderson ES,. Selection of unrelated compatible platelet donors by lymphocyte HLA matching. N Engl J Med 1973; 288: 760-764.
5. Kerkhoffs JL, Eikenboom JC, van de, Watering LM, van, Wordragen-Vlaswinkel RJ, Wijermans PW, Brand A,. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion 2008; 48: 1959-1965.
6. Toor AA, Choo SY, Little JA,. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplant 2000; 26: 315-320. (Pubitemid 30614413)
7. Meehan KR, Matias CO, Rathore SS, Sandler SG, Kallich J, LaBrecque J, Erder H, Schulman KA,. Platelet transfusions: utilization and costs in a tertiary hospital. Am J Hematol 2000; 64: 251-256. (Pubitemid 30622231)
8. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZ, Lister TA, Waters AH,. Relative importance of immune and nonimmune causes of platelet refractoriness. Vox Sang 1994; 66: 200-205. (Pubitemid 24103656)
9. Claas FH, Smeenk RJ, Schmidt R, van, Steenbrugge GJ, Eernisse JG,. Alloimmunization against MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 1981; 9: 84-89. (Pubitemid 11154352)
10. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337: 1861-1869.
11. Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY, Spinelli JJ, Sutherland HJ, Tsang P, Hogge DE,. Universal leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004; 103: 333-339. (Pubitemid 38029957)
12. Tosato G, Applebaum FR, Deisseroth AB,. HLA-matched platelet transfusion therapy of severe aplastic anemia. Blood 1978; 52: 846-854. (Pubitemid 9032656)
13. Duquesnoy RJ, Filip DJ, Aster RH,. Influence of HLA-A2 on the effectiveness of platelet transfusions in alloimmunized thrombocytopenic patients. Blood 1977; 50: 407-412. (Pubitemid 8180422)
14. Rodey GE, Neylan JF, Whelchel JD, Revels KW, Bray RA,. Epitope specificity of HLA Class I alloantibodies: I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994; 39: 272-280.
15. Vassallo RR,. New paradigms in the management of alloimmune refractoriness to platelet transfusions. Curr Opin Hematol 2007; 14: 655-663.
16. Petz LD, Garratty G, Calhoun L, Clark BD, Terasaki PI, Gresens C, Gornbein JA, Landaw EM, Smith R, Cecka JM,. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000; 40: 1446-1456. (Pubitemid 32048531)
17. Nambiar A, Duquesnoy RJ, Adams S, Zhao Y, Oblitas J, Leitman S, Stroncek D, Marincola F,. HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood 2006; 107: 1680-1687. (Pubitemid 43242409)
18. Freedman J, Gafni A, Garvey MB, Blanchette V,. A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients. Transfusion 1989; 29: 201-207. (Pubitemid 19141894)
19. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA,; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
20. Fowkes FG, Fulton PM,. Critical appraisal of published research: introductory guidelines. BMJ 1991; 302: 1136-1140.
21. Duquesnoy RJ, Filip DJ, Rodey GE, Rimm AA, Aster RH,. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977; 2: 219-226. (Pubitemid 8197618)
22. Pai SC, Lo SC, Lin Tsai SJ, Chang JS, Lin DT, Lin KS, Lin LI,. Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases. Transfusion 2010; 50: 2318-2327.
23. Messerschmidt GL, Makuch R, Appelbaum F, Ungerleider RS, Abrams R, O'Donnell J, Holohan TV, Fontana J, Wright D, Anagnou NP, Shan TC, Chesbro B, Deisseroth AB,. A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients. Cancer 1988; 62: 795-801.
24. Marktel S, Napolitano S, Zino E, Cappelli B, Chiesa R, Poli F, Crocchiolo R, Ronchi P, Rossini S, Ciceri F, Roncarolo MG, Fleischhauer K,. Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation. Pediatr Transplant 2010; 14: 393-401.
25. Levin MD, de Veld JC, van der Holt B, van't Veer MB,. Immune and nonimmune causes of low recovery from leukodepleted platelet transfusions: a prospective study. Ann Hematol 2003; 82: 357-362.
26. Hogge DE, McConnell M, Jacobson C, Sutherland HJ, Benny WB, Massing BG,. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients. Transfusion 1995; 35: 645-652.
27. Friedberg RC, Donnelly SF, Mintz PD,. Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients. Transfusion 1994; 34: 215-220. (Pubitemid 24109646)
28. Murphy MF, Metcalfe P, Thomas H, Eve J, Ord J, Lister TA, Waters AH,. Use of leucocyte poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 1986; 62: 529-534. (Pubitemid 16130188)
29. Ware R, Reisner EG, Rosse WF,. The use of radiolabeled and fluorescein-labeled antiglobulins in assays to predict platelet transfusion outcome. Blood 1984; 63: 1245-1248. (Pubitemid 14100932)
30. Dahlke MB, Weiss KL,. Platelet transfusion from donors mismatched for crossreactive HLA antigens. Transfusion 1984; 24: 299-302. (Pubitemid 14099941)
31. Hester JP, McCredie KB, Freireich EJ,. Platelet replacement therapy: a clinical assessment. Prog Clin Biol Res 1978; 28: 281-293.
32. MacPherson BR, Westphal RG,. Antileukocyte antibodies in patients refractory to platelet transfusions. Am J Clin Pathol 1979; 72: 893-897. (Pubitemid 10184817)
33. Wu KK, Hoak JC, Koepke JA, Thompson JS,. Selection of compatible platelet donors: a prospective evaluation of three cross-matching techniques. Transfusion 1977; 17: 638-643. (Pubitemid 8313917)
34. Herzig RH, Herzig GP, Bull MI, Decter JA, Lohrmann HP, Stout FG, Yankee RA, Graw RG Jr,. Correction of poor platelet transfusion responses with leukocyte-poor HL-A-matched platelet concentrates. Blood 1975; 46: 743-750.
35. Fontaine MJ, Kuo J, Chen G, Galel SA, Miller E, Sequeira F, Viele M, Goodnough LT, Tyan DB,. Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients. Transfusion 2011; 51: 2611-2618.
36. Levin MD, Kappers-Klunne M, Sintnicolaas K, van der, Holt B, van, Vliet HH, Löwenberg B, van't Veer MB,. The value of alloantibody detection in predicting response to HLA- matched platelet transfusions. Br J Haematol 2004; 124: 244-250. (Pubitemid 38122199)
37. McFarland JG, Anderson AJ, Slichter SJ,. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates. Br J Haematol 1989; 73: 380-386. (Pubitemid 20000232)
38. Heal JM, Blumberg N, Masel D,. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987; 70: 23-30. (Pubitemid 17111236)
39. Klingemann HG, Self S, Banaji M, Deeg HJ, Doney K, Slichter SJ, Thomas ED, Storb R,. Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases. Br J Haematol 1987; 66: 115-121. (Pubitemid 17071199)
40. Levy L, Woodfield DG,. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets. N Z Med J 1984; 97: 719-721. (Pubitemid 15129250)
41. McElligott MC, Menitove JE, Duquesnoy RJ, Hunter JB, Aster RH,. Effect of HLA Bw4/Bw6 compatibility on platelet transfusion responses of refractory thrombocytopenic patients. Blood 1982; 59: 971-975. (Pubitemid 12125586)
42. Daly PA, Schiffer CA, Aisner J, Wiernik PH,. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 1980; 243: 435-438. (Pubitemid 10207636)
43. Mittal KK, Ruder EA, Green D,. Matching of histocompatibility (HL-A) antigens for platelet transfusion. Blood 1976; 47: 31-41.
44. Lohrmann HP, Bull MI, Decter JA, Yankee RA, Graw RG Jr,. Platelet transfusions from HL-A compatible unrelated donors to alloimmunized patients. Ann Intern Med 1974; 80: 9-14.
45. Moroff G, Garratty G, Heal JM, MacPherson BR, Stroncek D, Huang ST, Ho W, Petz LD, Leach MF, Lennon SS, Rowe JM, Saleh MN, Arndt P, Foley K, Masel D, Postoway N,. Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 1992; 32: 633-640.
46. Bishop JF, McGrath K, Wolf MM, Matthews JP, De Luise T, Holdsworth R, Yuen K, Veale M, Whiteside MG, Cooper IA,. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988; 71: 383-387. (Pubitemid 18089526)
47. Brooks EG, MacPherson BR, Fung MK,. Validation of HLA Matchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions. Transfusion 2008; 48: 2159-2166.
48. Novotny VM,. Prevention and management of platelet transfusion refractoriness. Vox Sang 1999; 76: 1-13. (Pubitemid 29065240)
49. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R,. Factors affecting post-transfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105: 4106-4114. (Pubitemid 40656162)
50. International Forum. Detection of platelet-specific antibodies in patients who are refractory to platelet transfusions, and the selection of compatible donors. Vox Sang 2003; 84: 73-88.
51. Shah BR, Laupacis A, Hux JE, Austin PC,. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 2005; 58: 550-559. (Pubitemid 40692720)